Business Context and Reporting Period
This Form 8-K Current Report was filed by Amgen Inc. on April 22, 2026. The filing addresses a significant executive leadership change involving the retirement of the Executive Vice President and Chief Technology Officer.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on personnel changes and does not contain financial performance data.
Material Changes
- Executive Departure: David M. Reese is retiring from his role as Executive Vice President and Chief Technology Officer.
- Role Redistribution: Effective June 1, 2026, Dr. Reese's responsibilities will be redistributed among three executives:
- James E. Bradner (EVP, Research and Development, Artificial Intelligence and Data)
- Murdo Gordon (EVP, Amgen Global Markets and Policy)
- Peter H. Griffith (EVP and Chief Financial Officer)
- Transition Period: Dr. Reese will remain employed as an Executive Vice President until his official retirement on June 30, 2026.
Outlook, Risks, and Contingencies
Management Commentary: The restructuring is intended to facilitate the further integration of science, technology, and data, while building on the alignment of commercial, medical, and policy teams.
Compensation and Benefits: Upon departure on June 30, 2026, Dr. Reese will be retirement eligible and will receive benefits as described in the Company's plans and the 2026 Proxy Statement.
Risks and Contingencies: No specific financial risks or contingencies are detailed in this filing.
Investor Verification Checklist
- Verify the specific scope of responsibilities assigned to James E. Bradner, Murdo Gordon, and Peter H. Griffith following the redistribution.
- Review the 2026 Proxy Statement for details regarding Dr. Reese's retirement benefits and compensation.
- Monitor future filings for any impact on the company's technology and data integration strategy.